Wells Fargo & Company Alnylam Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 266,497 shares of ALNY stock, worth $67.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

266,497

Previous 206,148 29.27%

Holding current value

$67.7 Million

Previous $50.1 Million 46.34%

% of portfolio

0.02%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$233.81 - $287.01 $14.1 Million - $17.3 Million	60,349 Added 29.27%	266,497 $73.3 Million
Q2 2024 Aug 13, 2024	SELL	$143.31 - $247.0 $30,954 - $53,352	-216 Reduced 0.1%	206,148 $50.1 Million
Q1 2024 May 10, 2024	SELL	$146.51 - $198.2 $3.41 Million - $4.61 Million	-23,266 Reduced 10.13%	206,364 $30.8 Million
Q4 2023 Feb 09, 2024	SELL	$151.41 - $196.57 $5.47 Million - $7.1 Million	-36,105 Reduced 13.59%	229,630 $44 Million
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $1.15 Million - $1.42 Million	6,705 Added 2.59%	265,735 $47.1 Million
Q2 2023 Aug 15, 2023	BUY	$185.01 - $212.05 $2.69 Million - $3.09 Million	14,564 Added 5.96%	259,030 $49.2 Million
Q1 2023 May 12, 2023	BUY	$182.66 - $235.53 $8.23 Million - $10.6 Million	45,050 Added 22.59%	244,466 $49 Million
Q4 2022 Feb 13, 2023	BUY	$185.53 - $241.31 $25.2 Million - $32.7 Million	135,604 Added 212.51%	199,416 $47.4 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $1.25 Million - $2.09 Million	-8,996 Reduced 12.36%	63,812 $12.8 Million
Q2 2022 Aug 12, 2022	BUY	$120.42 - $169.29 $1.02 Million - $1.44 Million	8,499 Added 13.22%	72,808 $10.6 Million
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $2.43 Million - $3.33 Million	19,142 Added 42.38%	64,309 $10.5 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $14.5 Million - $19.1 Million	-91,083 Reduced 66.85%	45,167 $7.66 Million
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $1.79 Million - $2.2 Million	-10,570 Reduced 7.2%	136,250 $25.7 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $1.12 Million - $1.54 Million	-8,690 Reduced 5.59%	146,820 $24.9 Million
Q1 2021 May 13, 2021	SELL	$126.83 - $175.69 $8 Million - $11.1 Million	-63,066 Reduced 28.85%	155,510 $22 Million
Q4 2020 Feb 09, 2021	SELL	$122.97 - $147.0 $3.82 Million - $4.56 Million	-31,029 Reduced 12.43%	218,576 $28.4 Million
Q3 2020 Nov 05, 2020	BUY	$121.19 - $165.49 $928,194 - $1.27 Million	7,659 Added 3.17%	249,605 $36.3 Million
Q2 2020 Aug 13, 2020	SELL	$104.21 - $156.44 $769,903 - $1.16 Million	-7,388 Reduced 2.96%	241,946 $35.8 Million
Q1 2020 May 14, 2020	BUY	$93.12 - $133.99 $23.2 Million - $33.4 Million	249,334 New	249,334 $27.1 Million

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Alnylam Pharmaceuticals, Inc. Transaction History